NEW YORK, Dec. 15 (GenomeWeb News) - Friedrich von Bohlen, the CEO of Lion Bioscience, has announced his resignation, which will be effective December 31st, the Heidelberg, Germany company said today.
"Dr. von Bohlen and the supervisory board are convinced that Lion is now entering into a new phase of development that requires even stronger IT competence," the company said in a statement issued today. "With this milestone, Dr. von Bohlen proactively allows for new opportunities at Lion."
Von Bohlen, a dynamic and sometimes outspoken personality, founded the company and led it through its IPO in 2000, as well as the signing of major deals with Bayer, Celera, and IBM; the acquisition of NetGenics, and several rounds of restructuring and layoffs this year and last to refocus the company on its IT strengths.
Martin Hollenhorst, Chief Financial Officer, and Daniel Keesman, Chief Business Officer, will lead the company beginning Jan. 1.
The supervisory board has proposed that von Bohlen be elected as an additional member of the board at the next shareholders meeting on Aug. 12th.